Abstract #1463

CONSENSUS STATEMENT ON THE USE OF GADOLINIUM FOR MAGNETIC RESONANCE IMAGING USED IN THE DIAGNOSIS AND FOLLOW-UP OF PATIENTS WITH MULTIPLE SCLEROSIS

Jillian Katrina Chan¹, Anthony Traboulsee², Emanuel Kanal³, Kenneth Maravilla⁴, Lori Saslow⁵, Laura Barlow², Bruce Cohen⁶, Kathleen Costello⁷, June Halper⁸, Colleen Harris⁹, David Jones¹⁰, Flavia Nelson¹¹, Scott Newsome¹², Jiwon Oh¹³, Daniel Pelletier¹⁴, Kottil Rammonhan¹⁵, Daniel Reich¹⁶, Alex Rovira¹⁷, Lael Stone¹⁸, Kevin Terashima¹⁶, Jerry Wolinsky¹¹, and David Li²

¹Neurology, University of British Columbia, Vancouver, BC, Canada, ²University of British Columbia, Vancouver, BC, Canada, ³University of Pittsburgh Medical Center, Pittsburgh, PA, United States, ⁴University of Washington, Seattle, WA, United States, ⁵LS Science and Medical Communications, LLC, Great Neck, NY, United States, ⁶Northwestern University Medical SChool, Chicago, IL, United States, ⁷Nathional MS Society, Maryland, MD, United States, ⁸Consortium of MS Centers, Hackensack, NJ, United States, ⁹University of Calgary, Calgary, AB, Canada, ¹⁰University of Virginia, Charlottesville, VA, United States, ¹¹UT Health McGovern Medical School, Houston, TX, United States, ¹²Johns Hopkins Hospital, Baltimore, MD, United States, ¹³University of Toronto, Toronto, ON, Canada, ¹⁴Keck School of Medicine of USC, Los Angeles, CA, United States, ¹⁵University of Miami Multiple Sclerosis Center, Miami, FL, United States, ¹⁶Translational Neuroradiology Unit, NINDS, Bethesda, MD, United States, ¹⁷Section of Neuroradiology, Hospital Vall d'Hebron, Barcelona, Spain, ¹⁸Mellen Center for MS Treatment and Research, Cleveland, OH, United States

Clinical guidelines for the diagnosis and follow-up of multiple sclerosis recommends brain MR imaging with gadolinium based contrast agents. Our aim was to address concerns about the use of gadolinium, the risk of accumulation in the brain and propose changes to clinical guidelines published in 2016. Group consensus is that GBCA remain essential in the diagnostic evaluation of a patient suspected of having MS to demonstrate active inflammatory lesions. GBCA should be used judiciously, minimizing gadolinium exposure and dose when possible.

How to access this content:

For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.

After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.

After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.

Click here for more information on becoming a member.